Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, which are being presented at the Advanced Therapeutics in Movement & Related Disorders® (ATRMD) 2026 Congress on June 5, 2026.

GlobeNewsWire • 7 hours ago

Amneal Stock Up on FDA Nod for Romidepsin Injection Solution

AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a potential boost to its injectables portfolio.

Zacks Investment Research • 3 hours ago

Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution

Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approved its romidepsin injection solution, 27.5 mg/5.5 mL, in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy (CGT) designation, giving Amneal 180 days of market exclusivity.

Proactive Investors • Jun 4, 2026

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal's differentiated injectables portfolio BRIDGEWATER, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.

GlobeNewsWire • Jun 4, 2026

Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47th Annual Global Healthcare Conference 2026 being held on June 8-10 at the Loews Miami Beach Hotel in Miami, FL.

GlobeNewsWire • Jun 1, 2026

Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Jun 1, 2026

Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?

AMRX is building momentum with growth across specialty drugs and biosimilars, supported by new launches and a diversified portfolio.

Zacks Investment Research • May 26, 2026

Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • May 18, 2026

Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • May 15, 2026

3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)

Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • May 15, 2026